Login to Your Account



Pfizer Stalls Celltech Deal, Wants Bigger Profit Share

By Randall Osborne


Wednesday, November 19, 2003
Celltech Group plc said partner Pfizer Inc. has decided to delay development of the rheumatoid arthritis drug CDP 870, thereby stalling the potential launch for at least one year, and wants to renegotiate the terms of the companies' profit-sharing agreement. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription